Coming Soon

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxo

The purpose of the study is to compare the effects of glofitamab with combination of drugs. There will be two arms or groups. One group will receive glofitamab + Pola-R-CHP. The other group will receive only Pola-R-CHP. Pola-R-CHP includes: Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone

Age & Gender

18 years ~ 80 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Christopher Dittus
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Glands and Hormones

IRB Number

24-1335

ClinicalTrials.gov

NCT06047080

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.